对于业绩预减的主要原因，伟时电子表示，公司为保持行业技术领先而加大研发投入，导致利润承压； 子公司新建生产线的产能利用率处于爬升阶段，固定成本未能充分摊薄，影响了毛利率与营业利润；汇 率变动对利润影响方向发生逆转，较大程度拉低本期利润总额。 1月16日，伟时电子（605218）发布公告，公司预计2025年归母净利润为2149万元到2616万元，与上年 同期相比，预计减少3449万元到2982万元，同比减少61.61%到53.27%。扣除非经常性损益事项后，预 计归母净利润为837万元到1240万元，预计减少3816万元到3413万元，同比减少82.01%到73.35%。 ...

Group 1 - Xianghe Industrial signed a contract worth 43.1041 million yuan with China Railway 15th Bureau, accounting for approximately 6.5% of the company's projected revenue for 2024 [1] - Dayu Water-saving's subsidiary won a bid for a project valued at 133 million yuan, with a construction period of 545 days [2] - China National Materials International's subsidiary signed a contract worth 299 million Canadian dollars for engineering design and procurement services [3] Group 2 - Baoland expects a net loss of approximately 75 million yuan for 2025, compared to a loss of 58.7224 million yuan in the previous year [4] - Changhong High-tech received an administrative regulatory decision due to inadequate internal controls and improper revenue recognition [5] - Debon Stock will be suspended from trading on January 21, 2026, pending a decision on its delisting [6] Group 3 - Haitai Technology anticipates a net profit increase of 226.86% to 323.97% for 2025, with an expected profit of 51.5 million to 66.8 million yuan [7] - Fushun Special Steel expects a net loss of 770 million to 870 million yuan for 2025, compared to a profit of 112 million yuan in the previous year [8] - Rejing Bio forecasts a net loss of 210 million to 230 million yuan for 2025, compared to a loss of 191 million yuan in the previous year [10] Group 4 - Sanyou Chemical expects a net profit of approximately 91 million yuan for 2025, a decrease of about 82% compared to the previous year [11] - Lianhuan Pharmaceutical received approval for clinical trials of a new drug for benign prostatic hyperplasia [12] - Samsung New Materials anticipates a net loss for 2025, indicating a decline in operational performance [13] Group 5 - Jinggong Technology expects a net profit increase of 36.1% to 70.13% for 2025, with an estimated profit of 200 million to 250 million yuan [14] - Zhongsheng Pharmaceutical's subsidiary signed a licensing agreement for the production and commercialization of RAY1225 injection, with total payments expected to reach 1 billion yuan [15] - Hengshuai shares saw a reduction of 600,000 convertible bonds held by its controlling shareholder [16] Group 6 - Buchang Pharmaceutical plans to repurchase shares worth 60 million to 120 million yuan for employee stock ownership plans [17] - Baike Bio expects a net loss of 220 million to 280 million yuan for 2025, marking a shift from profit to loss [18] - Weishi Electronics anticipates a net profit decrease of 53.27% to 61.61% for 2025, with expected profits of 21.49 million to 26.16 million yuan [19] Group 7 - China Automotive Research expects a net profit increase of 17.85% for 2025, with a projected profit of 1.06 billion yuan [20] - Hualan Biological's controlling shareholder raised the upper limit of its shareholding plan to 86.66 yuan per share [22] - Nasda anticipates a net loss for 2025, indicating a decline in financial performance [23] Group 8 - Haizheng Pharmaceutical received a warning letter from the Zhejiang Securities Regulatory Commission for financial data inaccuracies [24] - Mengguli received an administrative regulatory decision for accounting errors in its financial reports [25] - Zhongguancun's subsidiary received acceptance for a drug application for a heart-related treatment [26] Group 9 - Hosheng Silicon Industry was ordered to correct information disclosure violations by the Zhejiang Securities Regulatory Commission [27] - Meiteng Technology expects a net profit decrease of 22.4551 million to 28.5285 million yuan for 2025, a reduction of 55.21% to 70.14% [28] - Sanwei Co. received a warning letter for financial irregularities related to related party transactions [29] Group 10 - Ganyue Expressway expects a net profit increase of 3.18% for 2025, with a projected profit of 1.32 billion yuan [30] - Xinhang New Materials plans to acquire 51% of Hairete for 12.8826 million yuan [31] - China Software anticipates a net loss of 41 million to 49 million yuan for 2025, an improvement from the previous year's loss [32] Group 11 - Rongsheng Development expects a net loss for 2025, with losses not exceeding the previous year's audited net assets [33] - Northern Rare Earth anticipates a net profit increase of 117% to 135% for 2025, with expected profits of 2.176 billion to 2.356 billion yuan [34] - Energy-saving Wind Power received renewable energy subsidies totaling 1.507 billion yuan, a 122.74% increase from the previous year [35] Group 12 - Dongzhu Ecology expects a net loss of 935 million to 1.135 billion yuan for 2025, compared to a loss of 630 million yuan in the previous year [36] - Jingneng Real Estate anticipates a net loss of 986 million to 1.315 billion yuan for 2025, compared to a loss of 109 million yuan in the previous year [37] - Hailu Heavy Industry signed new orders worth 1.941 billion yuan for 2025, with total orders on hand amounting to 3.597 billion yuan [38] Group 13 - Dalian Thermal Power expects a net loss of 92 million to 112 million yuan for 2025, compared to a loss of 146 million yuan in the previous year [39] - Jiangsu Sop expects a net profit decrease of 52.99% to 62.4% for 2025, with profits projected between 8 million to 10 million yuan [40] - Lian Technology plans to initiate preparations for issuing H-shares and listing on the Hong Kong Stock Exchange [42] Group 14 - Zhenyang Development expects a net profit decrease of 58.13% to 64.94% for 2025, with profits projected between 67 million to 80 million yuan [43] - Sheneng Co. reported a 1.7% decrease in power generation for 2025, with total generation of 57.654 billion kWh [44] - XGIMI Technology's subsidiary received a development notification from a well-known domestic automotive manufacturer [45] Group 15 - Wanhua Chemical's MDI Phase II facility resumed production after maintenance [46] - Daqing Energy expects a net loss of 1 billion to 1.3 billion yuan for 2025, with a reduction in losses compared to the previous year [47]

证券日报网讯1月16日，伟时电子（605218）发布公告称，公司预计2025年年度归属于上市公司股东的 净利润为2，149.00万元到2，616.00万元，与上年同期相比，预计减少3，449.41万元到2，982.41万元， 同比减少61.61%到53.27%。 ...

伟时电子（605218）(605218.SH)发布公告，公司预计2025年年度归属于上市公司股东的净利润为2149 万元到2616万元，与上年同期相比，预计减少3,449.41万元到2,982.41万元，同比减少61.61%到 53.27%。 报告期内，公司业绩预减的主要原因：一是公司为保持行业技术领先，持续加大研发投入，以致公司报 告期利润承压;二是子公司新建生产线产能利用率处于爬升阶段，其折旧、能耗、人员等固定成本未能 被充分摊薄，导致单位固定成本分摊较高，对当期毛利率与营业利润产生阶段性压力;三是汇率变动对 利润影响方向发生逆转，较大程度拉低本期利润总额。 ...

报告期内，公司业绩预减的主要原因：一是公司为保持行业技术领先，持续加大研发投入，以致公司报 告期利润承压;二是子公司新建生产线产能利用率处于爬升阶段，其折旧、能耗、人员等固定成本未能 被充分摊薄，导致单位固定成本分摊较高，对当期毛利率与营业利润产生阶段性压力;三是汇率变动对 利润影响方向发生逆转，较大程度拉低本期利润总额。 智通财经APP讯，伟时电子(605218.SH)发布公告，公司预计2025年年度归属于上市公司股东的净利润 为2149万元到2616万元，与上年同期相比，预计减少3,449.41万元到2,982.41万元，同比减少61.61%到 53.27%。 ...

人民财讯1月16日电，伟时电子（605218）1月16日公告，预计2025年度归属于上市公司股东的净利润为 2149万元到2616万元，同比减少53.27%—61.61%。报告期内，公司为保持行业技术领先，持续加大研 发投入，以致利润承压；汇率变动对利润影响方向发生逆转，较大程度拉低本期利润总额。 ...

格隆汇1月16日丨伟时电子（维权）(605218.SH)公布，经财务部门初步测算，预计2025年年度归属于上 市公司股东的净利润为2,149.00万元到2,616.00万元，同比减少61.61%到53.27%。扣除非经常性损益事 项后，公司预计2025年年度归属于上市公司股东的扣除非经常性损益的净利润为837.00万元到1,240.00 万元，同比减少82.01%到73.35%。 报告期内，公司业绩预减的主要原因：一是公司为保持行业技术领先，持续加大研发投入，以致公司报 告期利润承压；二是子公司新建生产线产能利用率处于爬升阶段，其折旧、能耗、人员等固定成本未能 被充分摊薄，导致单位固定成本分摊较高，对当期毛利率与营业利润产生阶段性压力；三是汇率变动对 利润影响方向发生逆转，较大程度拉低本期利润总额。 ...

● 业绩预告的具体适用情形：实现盈利，且归属于上市公司股东净利润与上年同 期相比下降 50%以上。 证券代码：605218 证券简称：伟时电子 公告编号：2026-001 伟时电子股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 二、上年同期业绩情况 ● 伟时电子股份有限公司（以下简称"伟时电子"或"公司"）预计 2025 年年 度归属于上市公司股东的净利润为 2,149.00 万元到 2,616.00 万元，与上年同期相比， 预计减少 3,449.41 万元到 2,982.41 万元，同比减少 61.61%到 53.27%。 ● 扣除非经常性损益事项后，公司预计 2025 年年度归属于上市公司股东的扣除 非经常性损益的净利润为 837.00 万元到 1,240.00 万元，与上年同期相比，预计减少 3,816.13 万元到 3,413.13 万元，同比减少 82.01%到 73.35%。 一、本次业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日到 20 ...

证券日报网讯1月13日，伟时电子（605218）在互动平台回答投资者提问时表示，截至2026年1月9日， 公司股东共18779户。 ...

证券日报网讯1月5日，伟时电子（605218）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东共19020户。 ...